ORAL THERAPEUTICS AND PHARMACOLOGY
Online ISSN : 1884-4928
Print ISSN : 0288-1012
ISSN-L : 0288-1012
Search
Advanced search
OR
Browse
Search
Volume 31, Issue 3
Displaying 1-4 of 4 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Original Article
  • Effect of 6-bromoindirubin-3'-oxime on human deciduous tooth dental pulp cells
    SAKI KAWAI, KYOKO HARADA, SACHIKO NAGATA, KIYOSHI OHURA, KENJI ARITA
    2012 Volume 31 Issue 3 Pages 87-95
    Published: December 01, 2012
    Released on J-STAGE: February 25, 2013
    DOIhttps://doi.org/10.11263/jsotp.31.87
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Stem cells have been a recent focus of regenerative medicine research. They originate from various tissues including human dental pulp containing human deciduous tooth dental pulp cells (hDPCs) that feature in the field of dentistry. However, only a very small number of stem cells are present in dental pulp tissue. It is known that 6-bromoindirubin-3'-oxime (BIO), a specific glycogen synthase kinase-3 (GSK-3) inhibitor, maintains the undifferentiated state of human and mouse embryonic stem cells. However, there are few reports that have applied BIO to hDPCs. Thus, we hypothesized that BIO may be necessary to maintain the undifferentiated state of hDPCs for clinical application. The aim of this study was to evaluate the effect of BIO on the undifferentiated state of hDPCs. hDPCs were extracted from the non-caries deciduous teeth of healthy children. BIO treatment at 0.5-1.5 μM slightly affected the proliferation of hDPCs, and 1-1.5 μM BIO induced the expression of Oct3/4 and Sox2 genes. Conversely, 0.5-1.5 μM BIO significantly reduced the gene expression of c-Myc as determined by real-time RT-PCR. Moreover, 1 μM BIO induced the expression of CD44 and CD90 as determined by flow cytometry. In summary, we found that 1 μM BIO was optimal for maintaining the undifferentiated state of hDPCs.
    View full abstract
    Download PDF (430K)
Case Report
  • A case of decreased serum cholinesterase caused by distigmine bromide for patient of carcinoma of the lower gingiva
    TAKAAKI KAMATANI, MIYUKI IKEDA, TOMOHIKO KUTSUNA, TAKEHIKO IIJIMA, YAS ...
    2012 Volume 31 Issue 3 Pages 96-100
    Published: December 01, 2012
    Released on J-STAGE: February 25, 2013
    DOIhttps://doi.org/10.11263/jsotp.31.96
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    Distigmine bromide is an anticholinesterase used to treat urinary retention. We describe a case of decreased serum cholinesterase caused by a usual oral dose of distigmine bromide for urinary retention. An 84-year-old man, who had been received chemotherapy for carcinoma of the lower gingiva, suddenly decreased serum cholinesterase to 21 IU/L in 7 days of administration of distigmine bromide 5mg without clinical symptoms. Serum cholinesterase improved after stopping the administration of distigmine bromide. This case shows that oral surgeons should be aware of the possibility of decreased serum cholinesterase in patients taking distigmine bromide.
    View full abstract
    Download PDF (672K)
Research Study
  • Efficacy of pregabalin therapy for patients with oral cancer in terminal stage
    RYUJI KANEKO, TAKURO KAWAGUCHI, TOUGO TOYA, KAZUTO OKABE, MINORU UEDA
    2012 Volume 31 Issue 3 Pages 101-107
    Published: December 01, 2012
    Released on J-STAGE: February 25, 2013
    DOIhttps://doi.org/10.11263/jsotp.31.101
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We have often experienced the uncontrollable situation for cancer pain, especially peripheral pain such as numb, burning, and tingling even if using NSAIDs and/or opioids. It is recommended for such neuropathic pain to use some adjuvant analgesics. Pregabalin was approved for treatment of peripheral neuropathic pain besides postherpetic neuralgia and diabetic peripheral neuropathy in 2010. We started to use the medicine for oral cancer patients accompanied with peripheral neuropathic pain. In this study we investigated the efficacy of pregabalin as additional therapy on each characteristics of cancer pain. We have experienced 6 cases with oral cancer in terminal stage using the medicine. In almost all cases, pain was reduced at the end of the observation period. We were able to gain a good management of peripheral pain treated with pregabalin.
    View full abstract
    Download PDF (1215K)
Study
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top